Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.

about

Clinical features of de novo CD25-positive follicular lymphoma.

P2860

Q50970668-E509D836-5AE0-4B97-B963-B151898C20B4

P2860

Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.

Item

http://www.wikidata.org/entity/Q45227780

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Clinical features of de novo CD25

@nl

Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.

@en

type

Item

label

Clinical features of de novo CD25

@nl

Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.

@en

prefLabel

Clinical features of de novo CD25

@nl

Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.

@en

P1476

Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.

@en

P2093

Akira Tanaka

http://www.w3.org/2001/XMLSchema#string

Katsutoshi Ozaki

http://www.w3.org/2001/XMLSchema#string

Kazuo Muroi

http://www.w3.org/2001/XMLSchema#string

Kazuya Sato

http://www.w3.org/2001/XMLSchema#string

Keiya Ozawa

http://www.w3.org/2001/XMLSchema#string

Ken Ohmine

http://www.w3.org/2001/XMLSchema#string

Masaki Mori

http://www.w3.org/2001/XMLSchema#string

Shin-ichiro Fujiwara

http://www.w3.org/2001/XMLSchema#string

Tadashi Nagai

http://www.w3.org/2001/XMLSchema#string

Takahiro Suzuki

http://www.w3.org/2001/XMLSchema#string

P2860

A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Tolerance, not immunity, crucially depends on IL-2.

Interleukin-2, interleukin-15, and their roles in human natural killer cells.

Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.

Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far.

P304

14-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/1607845412Y.0000000024

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22981118

http://www.w3.org/2001/XMLSchema#string

Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.

about

P2860

P2860

Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698